Thyroid Disorders in Women with Breast Cancer

Česká verzia

Authors: E. Hajtmanová ¹; P. Muríň ¹; I. Kinclová ¹; A. Hajtman ²; M. Péč ³; Ľ. Kostková ¹; M. Kočišová ¹
Authors place of work: Onkologické centrum, UN Martin, Slovenská republika ¹; Súdno-lekárske pracovisko Úradu pre dohľad nad zdravotnou starostlivosťou, pobočka Martin, Slovenská republika ²; Ústav lekárskej biológie, JLF UK Martin, Slovenská republika ³
Published in the journal: Klin Onkol 2012; 25(2): 124-129
Category: Original Articles

Summary

Aim:
Increasing prevalence of non-malignant thyroid disorders in women with breast cancer has been known for several decades; it is said to be associated with a better prognosis of the cancerous disease.

The aim of this work was to analyse associations between thyropathies found in women with breast cancer and particular prognostic factors.

Patients and Methods:
A group of 110 women with breast cancer were tested for autoimmune thyroiditis (AIT) and functional changes of the thyroid gland. Presence of thyroid-peroxidase autoantibodies (TPOAb), serum levels of thyroid-stimulating hormone (TSH) and free thyroxine (FT3, FT4) were determined after the surgery but before adjuvant cancer treatment (radiotherapy, chemotherapy or hormone therapy) initiation. Conventionally evaluated prognostic factors of breast cancer, including histological grading and molecular predictive factors (i.e. the status of the hormone receptors and the human epidermal growth factor receptor) were assessed – these were divided into four basic categories.

Results and Conclusions:
The incidence of AIT and subclinical hypothyroidism in the study group was 37.3% and 20%, respectively, i.e. higher than in the general population. The only correlation found was between thyropathies and the specific prognostic factors was that with G1 breast cancer grading.

Key words:
breast cancer – autoimmune thyroiditis – hypothyroidism – thyroid-stimulating hormone – free thyroxine – thyroid peroxidase – estrogen receptor – progesterone receptor – HER2 receptor

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
4. 8. 2011

Accepted:
13. 10. 2011

Zdroje

1. Cristofanilli M, Yamamura Y, Kau SW et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103(6): 1122–1128.

2. Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res 2003; 5(5): 235–238.

3. Carvalho ST, Stiepcich MM, Fregnani JH et al. Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. Clinics (Sao Paulo) 2011; 66(4): 607–612.

4. Goldhirsch A, Wood WC, Coates AS et al. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22(8): 1736–1747.

5. Podoba J. Najčastejšie tyreopatie v ambulanciii praktického lekára. Via Pract 2005; 2(5): 230–235.

6. Hrnčiar J. Racionálna diagnostika funkčných porúch štítnej žľazy v klinickej praxi. Interní Med 2006; 1: 18–23.

7. Zamrazil V. Subklinické tyreopatie. Interní Med 2004; 6: 295–299.

8. Vargová V, Pytliak M, Mechírová V. Hypotyreóza u seniorov. Čes Ger Rev 2010; 8(1–2): 22–26.

9. Riedel C, Dohán O, De la Vieja A et al. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. Trends Biochem Sci 2001; 26(8): 490–496.

10. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodine symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13(3): 797–826.

11. Venturi S, Donati FM, Venturi A et al. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Path 2000; 4(1): 11–17.

12. Smyth PP. Role of iodine in antioxidant defence in thyroid and breast disease. Biofactors 2003; 19(3–4): 121–130.

13. Cann SA, van Netten JP, Glover DW et al. Iodine accumulation in extrathyroidal tissues. J Clin Endokrinol Metab 1999; 84(2): 821–822.

14. Cann SA, van Netten JP, van Netten C. Hypothesis: iodine, selenium and the development of breast cancer. Cancer Causes Control 2000; 11(2): 121–127.

15. Kuijpens JL, Nyklíctek I, Louwman MW et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005; 15(11): 1253–1259.

16. Turken O, Narln Y, Demlrbas S et al. Breast cancer in association with thyroid disorders. Breast Cancer Res 2003; 5(5): R110–R113.

17. Smyth PP, Shering SG, Kilbane MT et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrinol Metab 1998; 83(8): 2711–2716.

18. Cutuli B, Quetin P, Rodier JF et al. Severe hypothyroidism after chemotherapy and locoregional irradiation for breast cancer. Radiother Oncol 2000; 57(1): 103–105.

19. Majkowska-Młynarczyk A, Kinalski M, Zaczek-Kucharska E. The thyroid gland function assessment in women after mastectomy and chemotherapy during breast cancer therapy. Endokrynol Pol 2007; 58(5): 397–402.

20. Zidan J, Rubenstein W. Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer. Oncology 1999; 56(1): 43–45.

21. Giustarini E, Pinchera A, Fierabracci P et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol 2006; 154(5): 645–649.

22. Sternberg EM. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol 2001; 169(3): 429–435.

23. Strieder TG, Prummel MF, Tijssen JG et al. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003; 59(3): 396–401.

24. Galbavý Š. Nové „markery a prognostické faktory“ z pohľadu patológa. Onkológia 2006; 1(3): 151–154.

25. Kajo K, Plank L. Význam analýzy génovej expresie v predpovedi prognózy a liečebnej odpovede pri karcinóme prsnej žľazy. Onkológia 2008; 3(4): 224–229.

26. Chen XS, Ma CD, Wu JY et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone rceptor and Her2 can predict the prognosis of breast cancer. Tumori 2010; 96(1): 103–110.

27. Yang Q, Chen J, Li HJ et al. Clinical features and prognosis analysis of different breast cancer molecular subtypes . Zhonghua Zhong Liu Za Zhi 2011; 33(1): 42–46.

28. Jiskra J. Racionální diagnostika a léčba nemocí štítné žlázy. Med Pro Praxi 2010; 7(4): 167–172.

29. Podoba J. Tyreopatie v ambulancii praktického lekára, alebo ako zvládnuť ich súčasnú „epidémiu“? Via Pract 2009; 6(4): 142–146.

30. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia-a novel paradigm. In Vivo 1996; 10(2): 245–247.

31. Davis FB, Tang HY, Shih A et al. Acting via a cell surface receptor, thyroid hormone is a grow factor for glioma cells. Cancer Res 2006; 66(14): 7270–7275.

32. Gail MH, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst 1994; 86(8): 573–575.

33. Grigerová M, Podoba J. Subklinické poruchy štítnej žľazy. Lek Obz 2010; 59(11): 444–448.

34. Jiskra J, Límanová Z, Barkmanová J et al. Prevalence autoimunitních tyreopatií u žen s karcinomem prsu ve srovnání s kolorektálním karcinomem. Klin Onkol 2003; 16(3): 149–153.

35. Muller I, Pinchera A, Fiore E et al. High prevalence of breast cancer in patients with benign thyroid diseases. J Endocrinol Invest 2010; 15(11): 1253–1259.